[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335931-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335931-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-the-pten-tumor-suppressor-gene-and-its-anti-angiogenic-activity-in-melanoma-and-other-cancers","The Role of the PTEN Tumor Suppressor Gene and Its Anti-Angiogenic Activity in Melanoma and Other Cancers","","Human malignant melanoma and other solid cancers are driven by tumor suppressor gene inactivation and angiogenesis. First-line surgery, radiation therapy, and chemotherapy often fail as monotherapies due to resistance and toxicity, prompting use of targeted angiogenesis inhibitors. This review highlights downregulation of PTEN in 30–40% of malignant melanomas, its regulation of PI3K/Akt and MAPK signaling, and PTEN-mediated suppression of angiogenesis via HIF-1α inhibition, discussing PTEN-upregulating phytochemical nanocarrier strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-the-pten-tumor-suppressor-gene-and-its-anti-angiogenic-activity-in-melanoma-and-other-cancers/335931/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-the-pten-tumor-suppressor-gene-and-its-anti-angiogenic-activity-in-melanoma-and-other-cancers/335931.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is angiogenesis a key factor in malignant melanoma and other solid cancers?","Question",{"text":63,"@type":64},"Angiogenesis is largely driven by dysregulated signaling and is supported by the inactivation of tumor suppressor genes, which contributes to tumor growth and progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PTEN influence cancer-related signaling pathways relevant to angiogenesis?",{"text":68,"@type":64},"PTEN regulates key pathways including PI3K/Akt and MAPK, which also drive angiogenesis. Its activity is modulated at transcriptional, translational, and post-translational levels.",{"name":70,"@type":61,"acceptedAnswer":71},"What role do PTEN-upregulating strategies and nanocarrier formulations play in targeted therapy?",{"text":72,"@type":64},"The review discusses inhibiting angiogenesis by upregulating PTEN and suppressing HIF-1α activity, and it also covers nanocarrier formulations designed to improve the pharmacokinetic profile and bioavailability of phytochemicals that enhance PTEN activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335931,1790196360,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","molecules   \nReview  \nThe Role of the PTEN Tumor Suppressor Gene and Its  \nAnti-Angiogenic Activity in Melanoma and Other Cancers  \nJacqueline Maphutha 1,*, Danielle Twilley 1 and Namrita Lall 1,2,3, *  \nCitation: Maphutha, J.; Twilley, D.; Lall, N. The Role of the PTEN Tumor Suppressor Gene and Its  \nAnti-Angiogenic Activity in Melanoma and Other Cancers. Molecules 2024, 29, 721. [https://](https://)[ ](https://)[doi.org/10.3390/molecules29030721](doi.org/10.3390/molecules29030721)  \nAcademic Editor: Peramaiyan Rajendran  \nReceived: 4 December 2023  \nRevised: 29 January 2024  \nAccepted: 1 February 2024  \nPublished: 4 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Plant and Soil Sciences, University of Pretoria, Pretoria 0002, South Africa  \n2 School of Natural Resources, University of Missouri, Columbia, MO 65211, USA  \n3 College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru 570015, India  \n* [Correspondence: jacquelinemaphu@gmail.com](Correspondence: jacquelinemaphu@gmail.com) (J.M.); [namrita.lall@up.ac.za](namrita.lall@up.ac.za) (N.L.); Tel.: +27-12-420-2524 (N.L.)  \nAbstract: Human malignant melanoma and other solid cancers are largely driven by the inactivation of tumor suppressor genes and angiogenesis. Conventional treatments for cancer (surgery, radiation therapy, and chemotherapy) are employed as first-line treatments for solid cancers but are often ineffective as monotherapies due to resistance and toxicity. Thus, targeted therapies, such as bevacizumab, which targets vascular endothelial growth factor, have been approved by the US Food and Drug Administration (FDA) as angiogenesis inhibitors. The downregulation of the tumor suppressor, phosphatase tensin homolog (PTEN), occurs in 30–40% of human malignant melanomas, thereby elucidating the importance of the upregulation of PTEN activity. Phosphatase tensin homolog (PTEN) is modulated at the transcriptional, translational, and post-translational levels and regulates key signaling pathways such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) pathways, which also drive angiogenesis. This review discusses the inhibition of angiogenesis through the upregulation of PTEN and the inhibition of hypoxia-inducible factor 1 alpha (HIF-1-α) in human malignant melanoma, as no targeted therapies have been approved by the FDA for the inhibition of angiogenesis in human malignant melanoma. The emergence of nanocarrier formulations to enhance the pharmacokinetic profile of phytochemicals that upregulate PTEN activity and improve the upregulation of PTEN has also been discussed.  \nKeywords: cancer; melanoma; angiogenesis; vascular endothelial growth factor; phosphatase tensin homolog; nanocarrier formulations  \n1. Introduction  \nCancer is one of the leading causes of death worldwide, relative to strokes and coronary heart disease. An estimated 19.3 million new cancer cases and 10 million new cancer deaths were recorded in 2020 . Furthermore, the global cancer burden has been predicted to increase by 47% from 2020 to 2040, highlighting the significance of developing new therapeutics in addition to the existing therapeutics to treat cancer [1] . Melanoma is the most lethal form of skin cancer and accounts for the majority of skin cancer-related deaths [2] . Melanoma can be classified as cutaneous melanoma, acral melanoma, mucosal melanoma, and uveal melanoma, which is dependent on where the melanoma arises from [3] . Cutaneous melanoma is the most common form of melanoma, with various subtypes such as superficial spreading melanoma (SSM), nodular melanoma (NM), lentigo ","cbCaif4AV7oTelRd","https://ap.wps.com/l/cbCaif4AV7oTelRd","pdf",811037,"English","# Abstract\n# 1. Introduction","[{\"question\":\"Why is angiogenesis a key factor in malignant melanoma and other solid cancers?\",\"answer\":\"Angiogenesis is largely driven by dysregulated signaling and is supported by the inactivation of tumor suppressor genes, which contributes to tumor growth and progression.\"},{\"question\":\"How does PTEN influence cancer-related signaling pathways relevant to angiogenesis?\",\"answer\":\"PTEN regulates key pathways including PI3K/Akt and MAPK, which also drive angiogenesis. Its activity is modulated at transcriptional, translational, and post-translational levels.\"},{\"question\":\"What role do PTEN-upregulating strategies and nanocarrier formulations play in targeted therapy?\",\"answer\":\"The review discusses inhibiting angiogenesis by upregulating PTEN and suppressing HIF-1α activity, and it also covers nanocarrier formulations designed to improve the pharmacokinetic profile and bioavailability of phytochemicals that enhance PTEN activity.\"}]","The Role of the PTEN Tumor Suppressor Gene and Its Anti-Angiogenic Activity in Melanoma and Other Cancers | PDF",1790012864,48]